Publications
A selected list of publications:
Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells Cancer biology & therapy. , 2004; 3(12): 1243-9.
Graham CA, Cloughesy TF Brain tumor treatment: chemotherapy and other new developments Seminars in oncology nursing. , 2004; 20(4): 260-72.
Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Investigational new drugs. , 2004; 22(4): 427-35.
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2004; 22(21): 4282-9.
Mischel PS, Cloughesy TF, Nelson SF DNA-microarray analysis of brain cancer: molecular classification for therapy Nature reviews. Neuroscience. , 2004; 5(10): 782-92.
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF Gene expression profiling of gliomas strongly predicts survival Cancer research. , 2004; 64(18): 6503-10.
Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J Prediction of neurocognitive outcome in adult brain tumor patients Journal of neuro-oncology. , 2004; 67(1-2): 245-53.
Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition Oncogene. , 2004; 23(6): 1283-90.
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma Journal of neuro-oncology. , 2004; 66(3): 365-75.
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-oncology. , 2004; 6(1): 44-54.
Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line Laboratory investigation; a journal of technical methods and pathology. , 2004; 84(1): 8-20.
Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF Gene expression profiling identifies molecular subtypes of gliomas Oncogene. , 2003; 22(31): 4918-23.
Mischel PS, Nelson SF, Cloughesy TF Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy Cancer biology & therapy. , 2003; 2(3): 242-7.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF Oncodiagnosis panel: 2002. Metastatic NSCLC Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF Oncodiagnosis panel: 2002. Patient’s symptoms not related to the lesion seen in the MR images Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2003; 21(12): 2305-11.
Mischel PS, Cloughesy TF Targeted molecular therapy of GBM Brain Pathol, 2003; 13(1): 52-61.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer research. , 2003; 63(11): 2742-6.
Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer. , 2003; 97(9 Suppl): 2381-6.
Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF Identification of molecular subtypes of glioblastoma by gene expression profiling Oncogene. , 2003; 22(15): 2361-73.
Biography
Dr. Cohen received his undergraduate training in both engineering at MIT and biology at Stanford. His graduate work at the Rockefeller University concerned hormonally-modulated electrical signaling. He worked in the private sector from 1985 to 1990 developing applications and technology of magnetic resonance imaging, before accepting a faculty appointment at Harvard, where he directed the high-speed MR imaging laboratory, and ultimately contributing to the development of functional MRI performing seminal experiments in this field. Since arriving at UCLA in 1993 he has focused his work on applications and technologies of neuroimaging, and more recently, has been working toward the development of low-cost high performance MRI devices based on novel technologies adopted from low temperature physics.